Association Between tDCS and Lokomat Training in Patients With Incomplete Spinal Cord Injury

NCT ID: NCT02562001

Last Updated: 2021-06-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-05-06

Study Completion Date

2018-05-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The spinal cord injury is identified as the major cause of permanent disability worldwide, with the loss of ability to walk being the largest and most devastating of them for these patients. Our goal is to analyze the effects of electrical transcranial direct-current stimulation (tDCS) combined with gait training with partial body weight support aided by robotic device (Lokomat, Hocoma) in the gait of patients with incomplete spinal cord injury (SCI). In this stratified randomized double-blind study, the participants will be randomly allocated into one of both groups, outpatients (GA) or inpatients (GI), and will receive active or placebo tDCS followed by gait training with Lokomat (GA: 3 sessions/week x 10 weeks = 30 sessions; GI: 5 sessions/week x 6 weeks = 30 sessions). The functional assessments (through clinical and functional scales, assess gait, muscle strength, spasticity, balance and pain) and neurophysiological (cortical excitability measured by transcranial magnetic stimulation, electroencephalography and functional near-infrared spectroscopy) will be held before and after the training period. The functional assessments will be also held after 15 sessions (intermediate) and after 3 months follow up. The expected result is that patients that received the active tDCS presents an improvement over the ground gait after the Lokomat training period significantly greater than the placebo group, with relations between neurophysiologic, kinematics and functional measurements.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The spinal cord injury is identified as the major cause of permanent disability worldwide, with the loss of ability to walk being the largest and most devastating of them for these patients. Therefore, our goal is to analyze the effects of the treatment with electrical transcranial direct-current stimulation (tDCS) associated with gait training with partial body weight support aided by robotic device (Lokomat, Hocoma) in the gait of patients with incomplete spinal cord injury (SCI) classified as AIS C and D. In this stratified randomized double-blind study, the participants will be randomly allocated into one of both groups, outpatients (GA) or inpatients (GI), and will receive active or placebo tDCS followed by gait training with Lokomat (GA: 3 sessions/week x 10 weeks = 30 sessions; GI: 5 sessions/week x 6 weeks = 30 sessions). The functional assessments (through clinical and functional scales, assess gait, muscle strength, spasticity, balance and pain) and neurophysiological (cortical excitability measured by transcranial magnetic stimulation, electroencephalography and functional near-infrared spectroscopy) will be held before and after the training period. The functional assessments will be also held after 15 sessions (intermediate) and after 3 months follow up. The expected result is that patients that received the active (tDCS) presents an improvement over the ground gait after the Lokomat training period, significantly greater than the placebo group, with positive correlation between neurophysiologic, kinematics and functional measurements.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spinal Cord Injuries

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Outpatient active group

This group will receive active tDCS, combined with Lokomat gait training

Group Type EXPERIMENTAL

Outpatient active group

Intervention Type DEVICE

active tDCS during 20 minutes before Lokomat training for outpatients

Inpatient active group

This group will receive active tDCS, combined with Lokomat gait training

Group Type EXPERIMENTAL

Inpatient active group

Intervention Type DEVICE

active tDCS during 20 minutes before Lokomat training for inpatients

Outpatient placebo group

This group will receive placebo tDCS, combined with Lokomat gait training

Group Type EXPERIMENTAL

Outpatient placebo group

Intervention Type DEVICE

placebo tDCS during 20 minutes before Lokomat training for outpatients

Inpatient placebo group

This group will receive placebo tDCS, combined with Lokomat gait training

Group Type EXPERIMENTAL

Inpatient placebo group

Intervention Type DEVICE

placebo tDCS during 20 minutes before Lokomat training for inpatients

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Outpatient active group

active tDCS during 20 minutes before Lokomat training for outpatients

Intervention Type DEVICE

Outpatient placebo group

placebo tDCS during 20 minutes before Lokomat training for outpatients

Intervention Type DEVICE

Inpatient active group

active tDCS during 20 minutes before Lokomat training for inpatients

Intervention Type DEVICE

Inpatient placebo group

placebo tDCS during 20 minutes before Lokomat training for inpatients

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

tDCS active tDCS placebo tDCS active tDCS placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical and radiological diagnosis of incomplete spinal cord injury of traumatic origin;
* 1 to 36 months of lesion;
* ASIA C and D;
* Stable clinical status;
* Cognitive function preserved in order to understand and execute the experiment and follow the instructions (Wechsler Adult Intelligence Scale - WASI 2014);
* Written informed consent;
* Tolerance to sit upright for at least 1 hour.

Exclusion Criteria

* Traumatic brain injury history, stroke, epilepsy and/or any other previous or concomitant neurological conditions to spinal cord injury;
* Presence of progressive neurodegenerative disease;
* Previous orthopedic problems (eg osteoarthritis, joint deformities);
* Member hypertonic (grade \> 3 on the modified Ashworth scale);
* Active/passive joint range of motion limitations;
* Irreversible muscle contractures;
* Lack of physical resistance during proposed physical training;
* Disabling fatigue;
* Body weight \> 150 Kg;
* Osteoporosis with pathological fracture risk;
* Asymmetry in the lower limbs \> 2 cm;
* Skin lesions and / or pressure ulcer in areas where the orthosis of Lokomat will press;


Skin lesions in the stimulation site; presence of electric, magnetic or mechanically activated implant (including cardiac pacemakers); intracerebral vascular clip or any other electrically sensitive device; pregnancy; metal in any part of the head; history of epilepsy resistant to medication; history of seizures or loss of consciousness not clarified and / or unaccompanied by a doctor.


Cardiac pacemaker; unstable angina or other decompensated heart disease; decompensated chronic obstructive pulmonary disease; unchecked autonomic dysreflexia that hinders Lokomat training; unhealed fracture of the bones of the lower limbs; tracheostomy; deformities and stiffness of the hip joint, knee ( ≥ 20° flexion) and ankle ( ≥ 10° plantar flexion).
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Sao Paulo General Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Linamara Rizzo Battistella, MD PhD

Professor of the Medical School, USP; Chairman of the Board of Medical and Physical Rehabilitation Institute (IMREA)

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Linamara Battistella, Md PhD

Role: PRINCIPAL_INVESTIGATOR

University of Sao Paulo

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Instituto de Medicina Física e Reabilitação, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo

São Paulo, , Brazil

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Brazil

References

Explore related publications, articles, or registry entries linked to this study.

Pai MYB, Terranova TT, Simis M, Fregni F, Battistella LR. The Combined Use of Transcranial Direct Current Stimulation and Robotic Therapy for the Upper Limb. J Vis Exp. 2018 Sep 23;(139):58495. doi: 10.3791/58495.

Reference Type RESULT
PMID: 30295660 (View on PubMed)

Simis M, Uygur-Kucukseymen E, Pacheco-Barrios K, Battistella LR, Fregni F. Beta-band oscillations as a biomarker of gait recovery in spinal cord injury patients: A quantitative electroencephalography analysis. Clin Neurophysiol. 2020 Aug;131(8):1806-1814. doi: 10.1016/j.clinph.2020.04.166. Epub 2020 May 22.

Reference Type RESULT
PMID: 32540720 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

43450715.7.0000.0068_CAAE

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.